InMed Pharmaceuticals Receives Nasdaq Extension

Inmed Pharmaceuticals Inc. (INM) has released an update.

InMed Pharmaceuticals Inc., a global leader in cannabinoid-based therapeutics, has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement for continued listing, which now gives the company until September 16, 2024, to achieve compliance. The company has already met all other listing requirements, and the stock will continue to trade under the symbol ‘INM’. InMed is considering various options, including a reverse stock split, to meet the bid price requirement.

For further insights into INM stock, check out TipRanks’ Stock Analysis page.